Next 10 |
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. “Collegium is pleased to welcome Nancy to our Board of Directors,” said Mik...
2025-01-20 05:42:47 ET Summary This article provides fundamental and momentum metrics for healthcare industries. The healthcare sector is currently overvalued by about 12% relative to 11-year averages, with pharmaceuticals/biotechnology showing the lowest value and quality scores....
2025-01-14 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2025-01-09 15:36:08 ET More on Bristol-Myers Squibb, Eli Lilly, etc. Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential Pfizer: A Step-By-Step Strategy Bef...
2025-01-08 11:25:04 ET More on Collegium Pharmaceutical Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Collegium Pharmaceutical, Inc. 2024 Q3 - Results - Earnings ...
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million –...
2024-12-17 15:32:56 ET More on Indivior Indivior PLC (INDV) Q3 2024 Earnings Call Transcript Indivior PLC 2024 Q3 - Results - Earnings Call Presentation Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 M&A deals...
2024-12-17 13:15:11 ET Summary This article provides a top-down analysis of the healthcare sector, focusing on fundamental and momentum metrics. Healthcare providers are reasonably valued, while other subsectors are overvalued by 9% to 21%, with pharmaceuticals/biotechnology being...
2024-11-26 08:00:00 ET Summary Collegium Pharmaceutical’s pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of Jornay PM expands COLL’s portfolio in...
2024-11-19 09:15:00 ET Summary The healthcare sector is overvalued by 18% relative to 11-year averages, with pharmaceuticals/biotechnology and healthcare equipment most overpriced. IXJ offers global healthcare exposure with lower concentration in top holdings compared to XLV, but ...
News, Short Squeeze, Breakout and More Instantly...
Collegium Pharmaceutical Inc. Company Name:
COLL Stock Symbol:
NASDAQ Market:
Collegium Pharmaceutical Inc. Website:
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. “Collegium is pleased to welcome Nancy to our Board of Directors,” said Mik...
2025-01-14 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million –...